Nature Reviews Clinical Oncology - Table of Contents alert Volume 12 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2015 Volume 12 Number 2
Impact Factor 15.696 *	In this issue Research Highlights Year in Review Reviews Perspectives Also this month  Featured article: Delirium in patients with cancer: assessment, impact, mechanisms and management Peter G. Lawlor & Shirley H. Bush
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation. Now open for submissions: http://bit.ly/1xXPzzM
RESEARCH HIGHLIGHTS Top Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer Published online: 23 December 2014 p63 | doi:10.1038/nrclinonc.2014.221 PDF Immunotherapy: Personalizing tumour vaccines Published online: 16 December 2014 p64 | doi:10.1038/nrclinonc.2014.220 PDF Haematological cancer: PD-1 blockade: opening the door to attack Published online: 23 December 2014 p65 | doi:10.1038/nrclinonc.2014.227 PDF Haematological cancer: ASPIRE for unprecedented benefit with carfilzomib in MM Published online: 23 December 2014 p65 | doi:10.1038/nrclinonc.2014.228 PDF Genetics: HotNet2—see the wood for the trees Published online: 06 January 2015 p66 | doi:10.1038/nrclinonc.2014.234 PDF Targeted therapies: New standard for ALK-positive NSCLC Published online: 06 January 2015 p66 | doi:10.1038/nrclinonc.2014.235 PDF Breast cancer: Tamoxifen—offering a long-term prevention option Published online: 13 January 2015 p66 | doi:10.1038/nrclinonc.2014.236 PDF IN BRIEF Gynaecological cancer: Olaparib is efficacious in patients with ovarian cancer | Urological cancer: Epigenetics in prostate cancer aggression and recurrence | Haematological cancer: Chemotherapy induces clonal selection of TP53 mutations | Urological cancer: Overcoming bladder cancer chemoresistance PDF Clinical Oncology JOBS of the week Assistant Professor of Molecular and Comparative Pathobiology Johns Hopkins University Shcool of Medicine Postdoctoral Research Fellow Memorial Sloan Kettering Cancer Center (MSKCC) Postdoctoral Fellow - MD Anderson Cancer Center MD Anderson Cancer Center Postdoctoral Position in Cancer Immunology Universität Basel Postdoctoral position in Blood Stem Cell Development and Cancers UT Southwestern Medical Center More Science jobs from Clinical Oncology EVENT 19th International Meeting of the European Society of Gynaecological Oncology 24.10.15 Nice, France More science events from
YEAR IN REVIEW		Top
Breast cancer in 2014: A call back to reality! Fatima Cardoso & Elżbieta Senkus Published online: 06 January 2015 p67 | doi:10.1038/nrclinonc.2014.226 In 2014, no major breakthroughs were made in understanding the biology of breast cancer or its management; few novel practice-changing studies were presented or published. Nevertheless, important negative results from studies that challenge some of the current concepts, particularly in drug development, underline 2014 as a year of 'failed surrogates and precocious expectations'. Full Text | PDF
Glioma in 2014: Unravelling tumour heterogeneity—implications for therapy David A. Reardon & Patrick Y. Wen Published online: 06 January 2015 p69 | doi:10.1038/nrclinonc.2014.223 Heterogeneity within and across tumours is increasingly recognized as a critical factor that limits therapeutic progress for many cancers. Key studies reported in 2014 describe previously unappreciated patterns of geographical and temporal heterogeneity for glioblastoma (the most-common primary CNS tumour in adults), with important implications for ongoing therapeutic studies evaluating molecular targeted therapies. Full Text | PDF
Multiple myeloma and chronic leukaemias in 2014: Improved understanding of disease biology and treatment Jesús F. San-Miguel & Hagop M. Kantarjian Published online: 16 December 2014 p71 | doi:10.1038/nrclinonc.2014.216 In 2014, strides were made in the care of haematological malignancies. In particular, the heterogeneity of multiple myeloma was unravelled, and new diagnostic criteria and frontline standards of care were proposed; new therapeutic approaches have been validated and approved in chronic lymphocytic leukaemia; and in chronic myeloid leukaemia, complete cytogenetic response was confirmed as the primary therapeutic end point. Full Text | PDF
Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies Joleen M. Hubbard & Axel Grothey Published online: 06 January 2015 p73 | doi:10.1038/nrclinonc.2014.233 The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease. Full Text | PDF | Supplementary information
Lung cancer in 2014: Optimizing lung cancer treatment approaches Rafael Rosell & Niki Karachaliou Published online: 23 December 2014 p75 | doi:10.1038/nrclinonc.2014.225 In 2014, developments in our understanding of escape signalling circuits implicated in resistance to targeted agents in patients with lung cancer have led to improvements in tackling such resistance. The potential role for PET in the management of erlotinib therapy, novel combination therapies and pharmacogenomic-driven individualization of platinum-based chemotherapy represent other key advances. Full Text | PDF
REVIEWS		Top
Delirium in patients with cancer: assessment, impact, mechanisms and management Peter G. Lawlor & Shirley H. Bush Published online: 02 September 2014 p77 | doi:10.1038/nrclinonc.2014.147 Delirium is a common neurocognitive manifestation in patients with cancer, particularly at advanced stages of the disease, and represents a considerable challenge for the patients, their families as well as health-care professionals involved in their care. This Review provides a comprehensive overview of the diagnosis, assessment, pathogenesis and management of delirium. The experiential impacts of delirium on patients with the condition, their family members and health-care practitioners are also discussed. Abstract | Full Text | PDF
Clinical trials of interventional oncology—moving from efficacy to outcomes James M. Franklin, Val Gebski, Graeme J. Poston & Ricky A. Sharma Published online: 09 December 2014 p93 | doi:10.1038/nrclinonc.2014.199 Interventional oncology aims to develop new disease-modifying treatment options beyond conventional surgical and oncological therapies. Clinical investigators should incorporate measures of cost-effectiveness and patient-reported outcomes into large-scale studies to provide robust evidence for changing clinical practice. In particular, interventional oncology trials could be designed to show that certain treatments might be as effective as the current standard of care, but with less morbidity and better outcomes for patients with cancer. Abstract | Full Text | PDF
Interventional oncology in multidisciplinary cancer treatment in the 21st century Andreas Adam & Lizbeth M. Kenny Published online: 02 December 2014 p105 | doi:10.1038/nrclinonc.2014.211 The new discipline of interventional oncology, a branch of interventional radiology, involves the treatment of cancer using highly technological image-guided ablation modalities, such as laser, radiofrequency and microwave ablation, cryoablation and electroporation. The roles of these techniques in oncology are not firmly established, although the evidence base is increasing. In this Review, the relationships between interventional radiology and other oncological disciplines are discussed. In particular, the potential benefit of collaboration between the fields of interventional oncology and radiation oncology is highlighted. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION The evolution of cancer surgery and future perspectives Lynda Wyld, Riccardo A. Audisio & Graeme J. Poston Published online: 11 November 2014 p115 | doi:10.1038/nrclinonc.2014.191 Surgery is the oldest oncological discipline and remains the cornerstone of treatment for most patients with cancer. However, the way surgery is used to treat cancer has evolved and outcomes continue to improve as a result of greater biological understanding, relentless technical innovation and a paradigm shift towards multimodal treatment. In this Perspectives, the authors discuss the developments in cancer surgery that have occurred over time and provide an overview of the key uses of surgery in the current era of multidisciplinary cancer care. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.